Nordic Nanovector: Share Options Granted, Including Options To Primary Insiders

OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces that the Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has decided to grant 510,000 share options in accordance with the proxy given by the Annual General Meeting held on 9 March 2015. Each option, when exercised, can acquire one share in Nordic Nanovector. The options are granted without consideration.

Back to news